Prednisolone Acetate

• A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pig… Not authorised
  2024-511181-36-00 Phase III 1 country Beacon Therapeutics (USA) Inc.
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting
  2022-501606-35-01 Phase III/IV 11 countries AbbVie Deutschland GmbH & Co. KG
• Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera… Recruiting
  2022-501220-14-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
• A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube… Recruiting
  2024-517184-23-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
• Pred Forte® versus placebo eye drops in chronic central serous chorioretinopathy trial (PICS trial) Recruiting
  2024-511575-15-00 Phase III 1 country Stichting Radboud University Medical Center
• A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic n… Recruiting
  2024-513489-20-00 Phase III 1 country Laboratorios Salvat S.A.
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended
  2023-506842-22-00 Phase I (FiH) 7 countries AbbVie Deutschland GmbH & Co. KG
• A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Rec… Ended
  2023-505617-24-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
• A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with advanced Epithelial Ovarian, P… Ended
  2024-516111-25-00 Phase III 1 country Immunogen Inc.

Showing 1–9 of 9 trials